COMMUNIQUÉS West-GlobeNewswire

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
04/06/2026
REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the [...]
WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland
04/06/2026
June 4, 2026 Seven-year collaboration puts WellSpan at the forefront of diagnostics and imaging in community health through a groundbreaking research and innovation strategy aimed at shaping the future of care delivery [...]
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
04/06/2026
REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Communiqué de presse : Sanofi lance son plan mondial 2026 d’actionnariat salarié
04/06/2026
Sanofi lance son plan mondial 2026 d’actionnariat salarié Paris, le 4 juin 202 6 . Sanofi lance Action 2026, son plan mondial d’actionnariat salarié, qui sera ouvert le 9 juin 2026 à plus de 75 000 salariés dans 52 pays [...]
Press Release: Sanofi launches 2026 global employee stock purchase plan
04/06/2026
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th [...]
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
04/06/2026
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis 1 Vanrafia reduced protein in urine by 38.3% vs placebo at 9 months [...]
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
04/06/2026
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application [...]
DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
04/06/2026
Dalton is a drug discovery platform integrating agentic AI, human expertise, and experimental data, into one continuous learning engine Announces collaboration with Sygnature Discovery, a leading integrated drug [...]
ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
04/06/2026
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present [...]
Valneva annonce la mise à disposition de la documentation relative à son Assemblée Générale annuelle
04/06/2026
Lyon (France), le 4 juin 2026 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins (« la Société »), a annoncé aujourd’hui la mise à disposition de la documentation relative à son [...]
Valneva Announces Availability of Documentation for its Annual General Meeting
04/06/2026
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting [...]
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
04/06/2026
Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at lower glucocorticoid [...]
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
04/06/2026
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds [...]
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
04/06/2026
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of [...]
Jade Biosciences Announces Pricing of Public Offering of Common Stock
04/06/2026
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
04/06/2026
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S. Buffalo, NY, June 03, 2026 (GLOBE NEWSWIRE) -- POP Biotechnologies, Inc. (“POP BIO”), a Buffalo-based biotechnology [...]
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
04/06/2026
LOUISVILLE, Ky., June 03, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
Main Results of 2026 Annual and Extraordinary General Meeting
03/06/2026
REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, [...]
Main Results of 2026 Annual and Extraordinary General Meeting
03/06/2026
The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg. All of the draft resolutions on the 2026 AGM [...]

Pages